Description
Key facts
Cell type:HEK-293T,
Species or organism:Human,
Tissue:Kidney,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon2 and Insertion of the selection cassette in exon2.
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-ARHGDIA, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
RhoGDI also known as Rho GDP-dissociation inhibitor 1 is a regulatory protein with a mass of approximately 23 kDa. It primarily inhibits the dissociation of GDP from Rho GTPases such as RhoA Rac1 and Cdc42. This protein plays an important role in controlling the cycling between active GTP-bound and inactive GDP-bound states of small GTPases. RhoGDI shows expression in numerous tissues highlighting its widespread regulatory functions in cell signaling.
Biological function summary
RhoGDI modulates the activity of Rho family GTPases—a group responsible for organizing the actin cytoskeleton which determines cell shape polarity and movement. It does not operate alone; rather it is part of a complex with membrane-bound and cytosolic proteins offering a shuttle service to balance GTPases between cellular locations. By doing so RhoGDI influences processes like cell migration and the cell cycle integral to maintaining proper cellular architecture.
Pathways
Scientists recognize RhoGDI’s participation in key signaling pathways particularly the Rho GTPase cycle and actin cytoskeleton organization. It interacts with proteins like ROCK and PAK within these pathways to achieve precise control of cytoskeletal dynamics. RhoGDI coordinates with these proteins to play a central role in cellular responses to external stimuli impacting processes like wound healing and cellular development.
RhoGDI has associations with cancer and neurodegenerative diseases. Its deregulation can disrupt the Rho GTPase pathways leading to uncontrolled cell proliferation in cancers such as breast and prostate cancer. Additionally altered RhoGDI function affects neuronal growth and survival linking it to neurodegenerative conditions like Alzheimer’s disease. Within these contexts RhoGDI interacts with other proteins such as Rac1 and Cdc42 to influence disease progression and pathology.
